Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3910499

CNCCCOc1cc(=O)oc2ccc(Cl)cc12.O=C(O)C(F)(F)F

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.51
▸ SMN1; SMN2 Q16637 4/20 0.51
▸ KDM4E B2RXH2 3/20 0.51
▸ LMNA P02545 2/20 0.51
▸ KCNA3 P22001 1/20 0.42
▸ HTR2C P28335 2/20 0.42
▸ PPARA Q07869 1/20 0.41
▸ CACNA1B Q00975 1/20 0.41
▸ MEN1 O00255 3/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ GAA P10253 1/20 0.40
▸ MCL1 Q07820 2/20 0.40
▸ TDP1 Q9NUW8 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3913361 0.91 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2KDM4ELMNAKCNA3
Trifluoroacetic Acid SCHEMBL3913356 0.87 HTR2C (0.45) ALDH1A1KDM4EKCNA3HTR2CPPARA
Trifluoroacetic Acid SCHEMBL3923252 0.86 KCNA3 (0.46) ALDH1A1KCNA3HTR2CPPARAMCL1
Trifluoroacetic Acid SCHEMBL3912558 0.86 HTR2C (0.39) ALDH1A1SMN1; SMN2KDM4ELMNAKCNA3
Trifluoroacetic Acid SCHEMBL5728404 0.86 HTR2C (0.44) ALDH1A1SMN1; SMN2KDM4EKCNA3HTR2C
Trifluoroacetic Acid SCHEMBL3911178 0.86 KCNA3 (0.59) KCNA3
Trifluoroacetic Acid SCHEMBL3925125 0.85 KCNA3 (0.45) ALDH1A1KCNA3HTR2CPPARAMCL1
Trifluoroacetic Acid SCHEMBL3911182 0.83 RHOC (0.42) L3MBTL1TSHRCYP1A2CYP2C9CYP2C19
SCHEMBL3922173 0.82 GFER (0.49) ALDH1A1KDM4ELMNAKCNA3MEN1
Trifluoroacetic Acid SCHEMBL3919734 0.80 HPGD (0.47) ALDH1A1SMN1; SMN2LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1667988-B1 COUMARINS AS INOS INHIBITORS AVENTIS PHARMA INC (US) 2013-04-10 — — EP disclosed
US-7538233-B2 Coumarins as iNOS inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2009-05-26 — — US disclosed
EP-1667988-A1 COUMARINS AS INOS INHIBITORS Aventis Pharmaceuticals Inc. (US) 2006-06-14 — — EP disclosed
WO-2005026143-A1 COUMARINS AS INOS INHIBITORS AVENTIS PHARMACEUTICALS INC. (US) 2005-03-24 — — WO disclosed
US-20050054681-A1 Coumarins as iNOS inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2005-03-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054681-A1 Coumarins as iNOS inhibitors NOS2, NOS1, NOS3 ALDH1A1 169/4885SMN1; SMN2 4820/4885KDM4E 3645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback